Announcement • Jun 17

Valerio Therapeutics Société Anonyme Announces CEO Changes

Valerio Therapeutics announced the appointment of Gilles Besin, Ph.D. as Chief Executive Officer by the Board of Directors, effective 1 July 2026, as well as the results of the votes at its shareholders’ general meeting held on 16 June 2026 (the "General Meeting"). As part of this governance transition, Julien Miara, having successfully led the Company through its strategic transformation, will step down from his role as Chief Executive Officer. Dr. Besin brings over two decades of experience in drug discovery, immunology, and RNA-based medicine, with a proven track record of building and scaling biotechnology companies through major value-creating milestones. Dr. Gilles Besin most recently served as Chief Scientific Officer of Orbital Therapeutics, a Cambridge, Massachusetts-based RNA medicine company, which was acquired by Bristol Myers Squibb in December 2025 for $1.5 billion. He subsequently joined BMS as Head of RNA and In Vivo CAR-T Cells and Site Head for the Cambridge Kendall Square campus. Prior to Orbital, he was Vice President and Head of Discovery Research at Affinivax, where he played a key role in the company's 2022 $3.3 billion acquisition by GlaxoSmithKline. Earlier in his career, Dr. Besin held research and development leadership roles at In-Cell-Art, Moderna, and several academic and translational research institutions, establishing deep expertise in immunology, nucleic acid therapeutics, and drug discovery platform development. Gilles Besin holds a Ph.D. and has built his career at the forefront of immunology and biotherapeutics. He has led scientific teams at leading biotech companies in both Europe and the United States, contributing to the development of vaccines, RNA medicines, and next-generation immunotherapies. His leadership has been instrumental in two major industry acquisitions totaling over $4.8 billion in combined value. Born in France, Dr. Besin brings both a global perspective and deep roots in European biotech innovation.

Valerio Therapeutics Société anonyme Stock Price

ALVIO Share Price Performance

ALVIO Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Valerio Therapeutics Société anonyme Key Details

About ALVIO

Recent ALVIO News & Updates

Now 50% overvalued after recent price rise

Valerio Therapeutics Société Anonyme Announces CEO Changes

Recent updates

Valerio Therapeutics Société anonyme Competitors

Boiron

Valneva

Eurobio Scientific Société anonyme